Breakthrough Medical Research in NEJM: Key Findings from Volume 394, Issue 20 (May 2026)
A groundbreaking Phase II trial published this week in the New England Journal of Medicine reveals that combining zanidatamab with tislelizumab significantly improves outcomes for HER2-positive gastroesophageal cancer patients, offering ... Read More